IL6 and posterior cortical atrophy: Although siltuximab (IL-6 inhibitor) impedes castration-resistant progression in androgen-dependent PCa xenograft models [187], no clinical benefit has been confirmed in two phase II clinical trials in metastatic CRPC patients (NCT00433446, NCT00385827).